Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Neoadjuvant nivolumab was associated with few side effects, did not delay surgery, and induced a major pathological response in 45% of resected tumors. The tumor mutational burd...
Publications
1 shownFrequent Co-Authors
Researcher Info
- h-index
- 1
- Publications
- 1
- Citations
- 2,056
- Institution
- Bloomberg (United States)
External Links
Identifiers
- ORCID
- 0000-0001-6925-6344
Impact Metrics
h-index
1
h-index: Number of publications with at least h citations each.